EE04001B1 - Peptiidne farmatseutiline kompositsioon - Google Patents

Peptiidne farmatseutiline kompositsioon

Info

Publication number
EE04001B1
EE04001B1 EEP199900545A EEP9900545A EE04001B1 EE 04001 B1 EE04001 B1 EE 04001B1 EE P199900545 A EEP199900545 A EE P199900545A EE P9900545 A EEP9900545 A EE P9900545A EE 04001 B1 EE04001 B1 EE 04001B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
peptide pharmaceutical
peptide
composition
pharmaceutical
Prior art date
Application number
EEP199900545A
Other languages
English (en)
Estonian (et)
Inventor
Richardson Peter
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/en
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE9900545A publication Critical patent/EE9900545A/xx
Publication of EE04001B1 publication Critical patent/EE04001B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EEP199900545A 1997-05-28 1998-05-26 Peptiidne farmatseutiline kompositsioon EE04001B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (en) 1997-05-28 1997-05-28 Pharmaceutical compositions of peptides having low solubility in physiological medium
EP97121246A EP0880969A1 (en) 1997-05-28 1997-12-03 Pharmaceutical compositions of peptides having low solubility in physiological medium
PCT/EP1998/003079 WO1998053844A1 (en) 1997-05-28 1998-05-26 Pharmaceutical compostions of peptides having low solubility in physiological medium

Publications (2)

Publication Number Publication Date
EE9900545A EE9900545A (et) 2000-06-15
EE04001B1 true EE04001B1 (et) 2003-04-15

Family

ID=26145485

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900545A EE04001B1 (et) 1997-05-28 1998-05-26 Peptiidne farmatseutiline kompositsioon

Country Status (27)

Country Link
US (1) US6331520B1 (no)
EP (2) EP0880969A1 (no)
JP (1) JP2002502384A (no)
KR (1) KR100552546B1 (no)
CN (1) CN1159062C (no)
AR (1) AR012868A1 (no)
AT (1) ATE252909T1 (no)
AU (1) AU743152B2 (no)
BG (1) BG64668B1 (no)
BR (1) BR9809708A (no)
CA (1) CA2291765A1 (no)
CZ (1) CZ298825B6 (no)
DE (1) DE69819322T2 (no)
DK (1) DK0984788T3 (no)
EA (1) EA002227B1 (no)
EE (1) EE04001B1 (no)
ES (1) ES2210772T3 (no)
HK (1) HK1029928A1 (no)
IL (2) IL133176A0 (no)
NO (1) NO323697B1 (no)
NZ (1) NZ500777A (no)
PL (1) PL192647B1 (no)
PT (1) PT984788E (no)
SI (1) SI0984788T1 (no)
SK (1) SK284640B6 (no)
TR (1) TR199902865T2 (no)
WO (1) WO1998053844A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
EP2142207A4 (en) * 2007-04-04 2013-01-16 Theratechnologies Inc PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
EP2906547B2 (en) * 2012-10-12 2022-10-26 L'Oréal Cosmetic compositions containing at least one hydrotrope and at least one active compound
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
CN109462982A (zh) 2016-02-16 2019-03-12 斯特朗布里奇都柏林有限公司 生理条件下具有较差溶解度的维多瑞肽用于治疗肢端肥大症、肢端肥大症癌症、sst-r5表达型肿瘤、ii型糖尿病、高血糖症和激素相关肿瘤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
AU641721B2 (en) * 1989-12-21 1993-09-30 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
JPH06510046A (ja) * 1991-08-26 1994-11-10 アボツト・ラボラトリーズ 治療薬の舌下または頬投与のための組成物及び方法
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
CA2123144A1 (en) * 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
TW280770B (no) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
AU3562195A (en) * 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
EP0984788B1 (en) 2003-10-29
PL336982A1 (en) 2000-07-31
CA2291765A1 (en) 1998-12-03
NZ500777A (en) 2001-09-28
CZ298825B6 (cs) 2008-02-20
SK159799A3 (en) 2000-07-11
KR100552546B1 (ko) 2006-02-14
NO323697B1 (no) 2007-06-25
AU743152B2 (en) 2002-01-17
EA002227B1 (ru) 2002-02-28
SI0984788T1 (en) 2004-02-29
AR012868A1 (es) 2000-11-22
CN1159062C (zh) 2004-07-28
EP0984788A1 (en) 2000-03-15
IL133176A0 (en) 2001-03-19
NO995763L (no) 1999-11-24
US6331520B1 (en) 2001-12-18
JP2002502384A (ja) 2002-01-22
DE69819322T2 (de) 2004-07-29
IL133176A (en) 2006-08-01
DE69819322D1 (de) 2003-12-04
EP0880969A1 (en) 1998-12-02
HK1029928A1 (en) 2001-04-20
WO1998053844A1 (en) 1998-12-03
BG64668B1 (bg) 2005-11-30
NO995763D0 (no) 1999-11-24
EA199901089A1 (ru) 2000-06-26
TR199902865T2 (xx) 2000-05-22
ES2210772T3 (es) 2004-07-01
PL192647B1 (pl) 2006-11-30
PT984788E (pt) 2004-01-30
BR9809708A (pt) 2000-07-11
CN1263469A (zh) 2000-08-16
EE9900545A (et) 2000-06-15
KR20010012253A (ko) 2001-02-15
BG103884A (en) 2000-07-31
CZ423199A3 (cs) 2000-05-17
ATE252909T1 (de) 2003-11-15
DK0984788T3 (da) 2004-03-08
SK284640B6 (sk) 2005-08-04
AU8106298A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
EE04294B1 (et) Farmatseutiline kompositsioon piperidinoalkanooldekongestandi kombineerimiseks
EE04440B1 (et) Kaparetseptori opioidpeptiidid ja farmatseutilinekompositsioon
DK0920302T3 (da) Farmaceutisk aerosolsammensætning
ID24654A (id) Formulasi farmasi omeprazola
NO980546D0 (no) Farmasöytiske midler
DK1017392T3 (da) Lægemiddel
EE04001B1 (et) Peptiidne farmatseutiline kompositsioon
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ID29294A (id) Komposisi farmasi
ID25857A (id) Komposisi farmasi
ID18698A (id) Komposisi farmasi
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
BR1100755A (pt) composição farmacêutica
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
ID21180A (id) Senyawa-senyawa farmasi
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
SE9804128D0 (sv) A new pharmaceutical composition
ID19162A (id) Komposisi farmasi yang mengandung trehalosa
DK1037604T3 (da) Farmaceutiske aerosolsammensætninger
FI3163U1 (fi) Lääkesäiliö
ID17133A (id) Komposisi farmasi
SE9601854D0 (sv) Farmaceutisk komposition
SE9604299D0 (sv) Pharmaceutical composition

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20080526